View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Research Reports
May 22, 2017

Type 2 Diabetes Leads Indications in Russian Clinical Trials, 2012-2016

GlobalData captured records of 1,825 clinical trials across all diseases and phases that had a start date between 2012 and 2016 with at least one clinical site location in Russia.

As part of GlobalData's series of white papers tracking clinical trials activity in emerging markets, the company covered Russia in January 2017.

GlobalData captured records of 1,825 clinical trials across all diseases and phases, which had a start date between 2012 and 2016 with at least one clinical site location in Russia.

Among all the indications for clinical trials in this dataset, the largest number of trials was carried out for type 2 diabetes, followed by rheumatoid arthritis, non-small cell lung cancer, asthma, and breast cancer. Based on the phase-wise distribution of clinical trials for the five major indications, Phase III trials were predominant. Type 2 diabetes was the indication with the most Phase III trials and the least number of Phase II trials as compared to other top five indications (see Figure 1).

Diabetes

Source: GlobalData, Pharma Intelligence Center, Clinical Trials Database [Accessed May 18, 2017]

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena